Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H25Cl2FO5 |
| Molecular Weight | 447.325 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 9 / 9 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@]12C[C@H](Cl)[C@@]3(Cl)[C@@H](C[C@H](F)C4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO
InChI
InChIKey=VTWKPILBIUBMDS-OTJLYDAYSA-N
InChI=1S/C21H25Cl2FO5/c1-18-4-3-10(26)5-13(18)14(24)6-12-11-7-16(27)21(29,17(28)9-25)19(11,2)8-15(22)20(12,18)23/h3-5,11-12,14-16,25,27,29H,6-9H2,1-2H3/t11-,12-,14-,15-,16+,18-,19-,20-,21-/m0/s1
Fluclorolone is a synthetic glucocorticoid corticosteroid which was never marketed. The acetonide cyclic ketal of fluclorolone, fluclorolone acetonide is a corticosteroid for topical use on the skin. Fluclorolone is a glucocorticoid receptor agonist. It was used for the treatment of atopic dermatitis, varicose eczema and psoriasis.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4601835
A double-blind trial comparing fluclorolone acetonide 0.025 % in FAPG base with the base alone was carried out on 18 female patients with varicose eczema. In 2 patients both legs were affected and treated. All the patients were routinely treated by compression sclerotherapy and the areas of eczema dressed once weekly with one or other of the creams until the eczema had cleared or there had been 4 visits with little or no improvement. Eight out of 10 patients treated with the active cream healed after one application and 1 patient after a second application, compared with only 1 patient healed and 1 showing some improvement on the base alone.
Route of Administration:
Topical
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
D07AC02
Created by
admin on Mon Mar 31 17:51:30 GMT 2025 , Edited by admin on Mon Mar 31 17:51:30 GMT 2025
|
||
|
WHO-VATC |
QD07AC02
Created by
admin on Mon Mar 31 17:51:30 GMT 2025 , Edited by admin on Mon Mar 31 17:51:30 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB13856
Created by
admin on Mon Mar 31 17:51:30 GMT 2025 , Edited by admin on Mon Mar 31 17:51:30 GMT 2025
|
PRIMARY | |||
|
CHEMBL3707231
Created by
admin on Mon Mar 31 17:51:30 GMT 2025 , Edited by admin on Mon Mar 31 17:51:30 GMT 2025
|
PRIMARY | |||
|
76962649
Created by
admin on Mon Mar 31 17:51:30 GMT 2025 , Edited by admin on Mon Mar 31 17:51:30 GMT 2025
|
PRIMARY | |||
|
036B9W83KK
Created by
admin on Mon Mar 31 17:51:30 GMT 2025 , Edited by admin on Mon Mar 31 17:51:30 GMT 2025
|
PRIMARY | |||
|
Fluclorolone
Created by
admin on Mon Mar 31 17:51:30 GMT 2025 , Edited by admin on Mon Mar 31 17:51:30 GMT 2025
|
PRIMARY | |||
|
4546
Created by
admin on Mon Mar 31 17:51:30 GMT 2025 , Edited by admin on Mon Mar 31 17:51:30 GMT 2025
|
PRIMARY | |||
|
DTXSID601317985
Created by
admin on Mon Mar 31 17:51:30 GMT 2025 , Edited by admin on Mon Mar 31 17:51:30 GMT 2025
|
PRIMARY | |||
|
3693-38-7
Created by
admin on Mon Mar 31 17:51:30 GMT 2025 , Edited by admin on Mon Mar 31 17:51:30 GMT 2025
|
PRIMARY | |||
|
108091
Created by
admin on Mon Mar 31 17:51:30 GMT 2025 , Edited by admin on Mon Mar 31 17:51:30 GMT 2025
|
PRIMARY | RxNorm |
ACTIVE MOIETY